XENON PHARMACEUTICALS INC (XENE) Forecast, Price Target & Analyst Ratings

NASDAQ:XENE • CA98420N1050

Current stock price

58.4 USD
-0.19 (-0.32%)
At close:
58.4 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for XENON PHARMACEUTICALS INC (XENE).

Forecast Snapshot

Consensus Price Target

Price Target
$81.42
+ 39.42% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$1.21
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
87.69%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$81.42
Upside
+ 39.42%
From current price of $58.40 to mean target of $81.42, Based on 26 analyst forecasts
Low
$50.50
Median
$81.60
High
$105.00

Price Target Revisions

1 Month
44.13%
3 Months
44.33%

Price Target Summary

26 Wall Street analysts provided a forecast for the next 12 months for XENE. The average price target is 81.42 USD. This implies a price increase of 39.42% is expected in the next year compared to the current price of 58.4.
The average price target has been revised upward by 44.33% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

XENE Current Analyst RatingXENE Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

XENE Historical Analyst RatingsXENE Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20 25

Analyst Ratings Consensus

ChartMill Buy Consensus
87.69%
XENE was analyzed by 26 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about XENE.
In the previous month the buy percentage consensus was at a similar level.
XENE was analyzed by 26 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-16WedbushMaintains Outperform -> Outperform
2026-03-10Deutsche BankMaintains Buy -> Buy
2026-03-10WedbushMaintains Outperform -> Outperform
2026-03-10Wells FargoMaintains Overweight -> Overweight
2026-03-10HC Wainwright & Co.Maintains Buy -> Buy
2026-03-09NeedhamMaintains Buy -> Buy
2026-03-09BairdMaintains Outperform -> Outperform
2026-02-27NeedhamMaintains Buy -> Buy
2026-02-27Wells FargoMaintains Overweight -> Overweight
2026-02-24Wolfe ResearchInitiate Outperform
2026-01-09JP MorganMaintains Overweight -> Overweight
2025-12-11Wells FargoMaintains Overweight -> Overweight
2025-11-18JP MorganMaintains Overweight -> Overweight
2025-11-04NeedhamReiterate Buy -> Buy
2025-11-04RBC CapitalMaintains Outperform -> Outperform
2025-11-04Wells FargoMaintains Overweight -> Overweight
2025-10-07Chardan CapitalMaintains Buy -> Buy
2025-09-02RBC CapitalReiterate Outperform -> Outperform
2025-08-12Chardan CapitalMaintains Buy -> Buy
2025-08-12RBC CapitalMaintains Outperform -> Outperform
2025-08-12WedbushMaintains Outperform -> Outperform
2025-05-14Evercore ISI GroupInitiate Outperform
2025-05-13Chardan CapitalMaintains Buy -> Buy
2025-05-13NeedhamMaintains Buy -> Buy
2025-05-13RBC CapitalMaintains Outperform -> Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$1.21
Revenue Estimate
Revenue Q2Q
-100.00%
EPS Q2Q
-45.53%
Number of Analysts
19

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.79%
EPS (3 Months)
-4.89%

Next Earnings Summary

XENE is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -1.21 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
XENE revenue by date.XENE revenue by date.

-100.00%		7.5M4.151M
-44.65%		105.28M
2,436.26%		304.1M
188.85%		712.06M
134.15%		1.059B
48.72%		1.391B
31.35%		1.738B
24.95%		2.012B
15.77%
EBITDA
YoY % growth
XENE ebitda by date.XENE ebitda by date.
-211.993M
-66.24%		-276.738M
-30.54%		-370.527M
-33.89%		-430.92M
-16.30%		-412.574M
4.26%		-329.727M
20.08%		-68.252M
79.30%		357.16M
623.30%		N/AN/AN/A
EBIT
YoY % growth
XENE ebit by date.XENE ebit by date.
-214.054M
-65.75%		-279.298M
-30.48%		-373.07M
-33.57%		-448.059M
-20.10%		-441.927M
1.37%		-256.444M
41.97%		106.93M
141.70%		389.58M
264.33%		631.27M
62.04%		878.69M
39.19%		1.075B
22.34%
Operating Margin
XENE operating margin by date.XENE operating margin by date.
N/AN/A-4,974.27%-10,793.99%-419.76%-84.33%15.02%36.79%45.38%50.56%53.43%
EPS
YoY % growth
XENE eps by date.XENE eps by date.
-2.72
-33.33%		-3.02
-11.03%		-4.36
-44.37%		-4.86
-11.36%		-4.71
3.04%		-2.71
42.33%		-0.06
97.63%		3.03
4,813.97%		4.05
33.75%		6.81
67.98%		8.95
31.55%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-1.21
-45.53%		-1.19
-10.87%		-1.22
-5.76%		-1.24
5.21%		-1.22
-1.05%		-1.28
-8.05%		-1.28
-5.39%		-1.30
-4.87%
Revenue
Q2Q % growth
-100.00%		1.093M2.376MN/A102K
-90.67%		2.234M6.62M
178.62%
EBITDA
Q2Q % growth		-102.916M
-42.78%		-105.721M
-13.75%		-109.48M
-15.97%		-113.766M
-6.10%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-108.536M
-49.21%		-110.354M
-17.11%		-113.583M
-17.90%		-115.72M
-5.42%		-105.084M
3.18%		-109.414M
0.85%		-109.869M
3.27%		-113.478M
1.94%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 -4 6 8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
11.26%
EPS Next 5 Year
21.93%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
247.40%
Revenue Next 5 Year
170.94%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
3.38%
EBIT Next 5 Year
24.32%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

XENON PHARMACEUTICALS INC / XENE Forecast FAQ

What is the price target for XENE stock?

26 analysts have analysed XENE and the average price target is 81.42 USD. This implies a price increase of 39.42% is expected in the next year compared to the current price of 58.4.

When does XENON PHARMACEUTICALS INC (XENE) report earnings?

XENON PHARMACEUTICALS INC (XENE) will report earnings on 2026-05-11, after the market close.

What are the consensus estimates for XENON PHARMACEUTICALS INC (XENE) next earnings?

The consensus EPS estimate for the next earnings of XENON PHARMACEUTICALS INC (XENE) is -1.21 USD and the consensus revenue estimate is 0 USD.

Can you provide the analyst count for XENON PHARMACEUTICALS INC stock?

The number of analysts covering XENON PHARMACEUTICALS INC (XENE) is 26.